Allogeneic NK Cells with a Bispecific Innate Cell Engager in Refractory Relapsed Lymphoma: A Phase I Trial

The authors studied cord-blood-derived cytokine-preactivated and expanded NK cells precomplexed with AFM13 in patients with CD30+ lymphoma refractory to brentuximab vedotin and anti-PD1 checkpoint inhibitors.